Polyrizon (PLRZ) announced that it has entered into an agreement with a globally recognized branding and trademark consultancy firm, renowned for working with leading pharmaceutical and medical device companies worldwide. Under this collaboration, the firm will develop a strategic brand name and identity for Polyrizon’s proprietary Capture and Contain hydrogel technology, an innovative intranasal spray formulation designed to create a protective biological barrier against allergens and viruses. This initiative marks a crucial step forward in Polyrizon’s pathway to commercialize its technology and effectively communicate its unique benefits to the market. Polyrizon anticipates completing the brand development process in alignment with its ongoing clinical and regulatory milestones.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRZ:
- Polyrizon Ltd. Secures $17 Million in Private Placement to Advance Hydrogel Technology
- Polyrizon announces $17M private placement
- Polyrizon Prepares Clinical Strategy for Allergy Blocker PL-14
- Polyrizon structures clinical strategy for allergy blocker PL-14
- Polyrizon begins BZDs studies for treating ARS and status epilepticus
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue